-+ 0.00%
-+ 0.00%
-+ 0.00%

On July 29, Yinnuo Pharmaceutical announced that the Phase IB clinical trial of the company's self-developed ultra-long-acting GLP-1 receptor agonist esupaglutide α for adolescent obesity indications has completed its first patient enrollment in China. Currently, the company is carrying out a phase II clinical trial for obesity indications in Australia to explore a monthly dosage plan. Currently, no weight loss drugs for children and adolescents have been approved for marketing in our country.

Zhitongcaijing·07/29/2026 01:17:05
Listen to the news
On July 29, Yinnuo Pharmaceutical announced that the Phase IB clinical trial of the company's self-developed ultra-long-acting GLP-1 receptor agonist esupaglutide α for adolescent obesity indications has completed its first patient enrollment in China. Currently, the company is carrying out a phase II clinical trial for obesity indications in Australia to explore a monthly dosage plan. Currently, no weight loss drugs for children and adolescents have been approved for marketing in our country.